Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) CFO David Thomas Evans acquired 50,000 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was purchased at an average price of $0.63 per share, for a total transaction of $31,500.00. Following the completion of the acquisition, the chief financial officer owned 317,930 shares in the company, valued at approximately $200,295.90. This trade represents a 18.66% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
David Thomas Evans also recently made the following trade(s):
- On Friday, May 15th, David Thomas Evans acquired 150,000 shares of Cardlytics stock. The stock was purchased at an average price of $0.65 per share, for a total transaction of $97,500.00.
Cardlytics Price Performance
Cardlytics stock opened at $0.73 on Friday. The stock’s 50-day moving average is $0.87 and its 200-day moving average is $1.03. The company has a market cap of $41.97 million, a price-to-earnings ratio of -0.41 and a beta of 0.67. Cardlytics, Inc. has a 12 month low of $0.57 and a 12 month high of $3.28.
Institutional Investors Weigh In On Cardlytics
A number of large investors have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC acquired a new stake in Cardlytics during the 3rd quarter valued at approximately $26,000. Virtu Financial LLC acquired a new stake in Cardlytics during the 4th quarter valued at approximately $39,000. Qube Research & Technologies Ltd acquired a new stake in Cardlytics during the 3rd quarter valued at approximately $55,000. Marshall Wace LLP acquired a new stake in Cardlytics during the 2nd quarter valued at approximately $59,000. Finally, Renaissance Technologies LLC acquired a new stake in Cardlytics during the 4th quarter valued at approximately $62,000. Institutional investors and hedge funds own 68.10% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research firms have recently issued reports on CDLX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cardlytics in a research note on Friday, April 10th. Wall Street Zen upgraded Cardlytics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Lake Street Capital set a $1.00 target price on Cardlytics in a research note on Friday, May 8th. Bank of America reiterated an “underperform” rating on shares of Cardlytics in a research note on Thursday, March 5th. Finally, Evercore set a $1.00 target price on Cardlytics in a research note on Friday, March 6th. One analyst has rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Sell” and an average price target of $1.00.
View Our Latest Analysis on CDLX
Cardlytics Company Profile
Cardlytics, Inc operates a purchase intelligence and marketing platform that connects advertisers with consumers through bank and credit card transaction data. The company partners with financial institutions to analyze anonymized purchase information, enabling brands to deliver highly targeted offers and rewards directly to customers’ online and mobile banking channels. By leveraging real-time insights into consumer spending habits, Cardlytics helps marketers optimize campaign performance and measure return on ad spend more accurately than traditional digital advertising methods.
At the core of Cardlytics’ offering is its proprietary purchase intelligence engine, which aggregates and anonymizes transaction data from partner banks and credit unions.
Further Reading
- Five stocks we like better than Cardlytics
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.
